Gene Biotherapeutics, Inc. – OTC:CRXM
Gene Biotherapeutics stock price today
Gene Biotherapeutics stock price monthly change
Gene Biotherapeutics stock price quarterly change
Gene Biotherapeutics stock price yearly change
Gene Biotherapeutics key metrics
Market Cap | 6.49K |
Enterprise value | 327.35K |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | -0.71 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.01 |
Revenue | N/A |
EBITDA | -1.26M |
Income | -559.37K |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGene Biotherapeutics stock price history
Gene Biotherapeutics stock forecast
Gene Biotherapeutics financial statements
| Mar 2020 | 0 | -165.69K | |
|---|---|---|---|
| Jun 2020 | 0 | 435.78K | |
| Sep 2020 | 0 | -373.83K | |
| Dec 2020 | 0 | -455.63K |
| Mar 2020 | 129674 | 5.14M | 3970.15% |
|---|---|---|---|
| Jun 2020 | 1341837 | 5.01M | 374.05% |
| Sep 2020 | 974817 | 5.05M | 518.41% |
| Dec 2020 | 566982 | 5.13M | 905.71% |
| Mar 2020 | -93.85K | 0 | 96.38K |
|---|---|---|---|
| Jun 2020 | -221.48K | 0 | 1.53M |
| Sep 2020 | -479.79K | 0 | -47.67K |
| Dec 2020 | -337.86K | -4 | -57.67K |
Gene Biotherapeutics alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 3 |
| Nov 2023 | 3 |
| Dec 2023 | 3 |
| Jan 2024 | 3 |
| Feb 2024 | 3 |
| Mar 2024 | 3 |
| Apr 2024 | 3 |
| May 2024 | 3 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
Gene Biotherapeutics other data
-
What's the price of Gene Biotherapeutics stock today?
One share of Gene Biotherapeutics stock can currently be purchased for approximately $0.
-
When is Gene Biotherapeutics's next earnings date?
Unfortunately, Gene Biotherapeutics's (CRXM) next earnings date is currently unknown.
-
Does Gene Biotherapeutics pay dividends?
No, Gene Biotherapeutics does not pay dividends.
-
How much money does Gene Biotherapeutics make?
Gene Biotherapeutics has a market capitalization of 6.49K.
-
What is Gene Biotherapeutics's stock symbol?
Gene Biotherapeutics, Inc. is traded on the OTC under the ticker symbol "CRXM".
-
What is Gene Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gene Biotherapeutics?
Shares of Gene Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Gene Biotherapeutics have?
As Jul 2024, Gene Biotherapeutics employs 3 workers.
-
When Gene Biotherapeutics went public?
Gene Biotherapeutics, Inc. is publicly traded company for more then 25 years since IPO on 3 May 2000.
-
What is Gene Biotherapeutics's official website?
The official website for Gene Biotherapeutics is genebiotherapeutics.com.
-
Where are Gene Biotherapeutics's headquarters?
Gene Biotherapeutics is headquartered at 11230 Sorrento Valley Road, San Diego, CA.
-
How can i contact Gene Biotherapeutics?
Gene Biotherapeutics's mailing address is 11230 Sorrento Valley Road, San Diego, CA and company can be reached via phone at 858 414 1477.
Gene Biotherapeutics company profile:
Gene Biotherapeutics, Inc.
genebiotherapeutics.comOTC
3
Biotechnology
Healthcare
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.
San Diego, CA 92121
CIK: 0000772320
ISIN: US8767671048
CUSIP: 876767104
